REFERENCES
- Alan L., Miller N. D. Antioxidants: Structure function and clinical usage. Alternative Medicine Review 1996; 1(2)103–111
- Annapurna A., Krishna K. M., Gopal G. S., Chalam S. G. R., Madan K., Kumar V. K., Prakash G. J. Partial reversal by rutin and quercetin of impaired cardiac function in streptozotocin-induced diabetic rats. Can. J. Physiol. Pharmacol. 2005; 3(4)343–355
- Bronner C., Landry Y. Kinetics of inhibitory effect of flavonoids on histamine secretion from mast cells. Agents Actions 1985; 16: 147–151
- Buchi N. N., Chowdary K. P. R., Murthy K. V. R., Hayman A. R., Becket G. Physicochemical characterization and dissolution properties of nimesulide-binary systems. AAPS Pharm. Sci. Tech. 2003; 4(1)1–11
- Calabro M. L., Tommasini S., Donato P., Stancanelli R., Raneri D., Catania S., Costa C., Villari V., Ficarra P., Ficcara R. The rutin/β-CD interactions in fully aqueuous solution: spectroscopic studies and biological assays. J. Pharm. Biomed. Anal 2005; 36(5)1019–1018
- Challa R., Ahuja A., Ali J., Khar R. K. Cyclodextrins in drug delivery: An update review. AAPS Pharm. Sci. Tech. 2005; 6(2)329–357
- Degroot H., Rauen U. Tissue injury by reactive oxygen species and the protective effects of flavonoiods. Fundam. Clin. Pharmacol. 1998; 12: 249–255
- Haiyun D., Jianbin C., Zhang G. M., Shaomin S., Jinhao P. Preparation and spectral investigation on inclusion complex of cyclodextrin with rutin. Spectrochimica Acta Part A Mol Biomol Spectrosc 2003; A59: 3421–3429
- Hertog M. G., Feskens E. J., Hollman P. C. H., Katan M. B, Kromhout D. Dietary antioxidant flavonoids and risks of coronary heart disease: the zutphen elderly study. Lancet 1993; 342: 1007–1011
- Hertog M. G. L., Hollman P. C. H., Katan M. B., Kromhout D. In take of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 1993; 20: 21–29
- Higuchi T., Connors K. A. Phase solubility techniques. Advances in Analytical Chemistry Instrumentation, C. N. Reilly. Interscience, New York 1965; 4: 117–212
- Hollman P. C. H., van Trijp J. M., Buysman M. N., van der Gaag M. S., Mengelers M. J., de Vries J. H., Katan M. B. Relative bioavail-ability of the antioxidant flavonoid quercetin from various foods in man. FEBS Letters 1997; 418: 152–156
- Kaul T. N., Middleton E., Jr., Ogra P. L. Antiviral effect of flavonoids on human viruses. J. Med. Virol. 1985; 15: 71–79
- Khan K. A. The concept of dissolution efficiency. J. Pharm Pharmacol. 1975; 27: 48–49
- Liu L., Zhu S. Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-CD and HP-β-CD. J. Pharm. Biomed. Anal. 2006; 40: 122–127
- Ljungman A. G., Tagesson C., Lindahl M. Endotoxin stimulates the expression of group II PLA2 in rat lung in vivo and in isolated perfused lungs. Am. J. Physiol 1996; 5(Pt 1)L752–760
- Loftsson T., Brewster M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996; 85(10)1017–1025
- Monograph on Quercetin. Alternative Medicine Review 1998; 3(2)140–143
- Pralhad T., Rajendrakumar K. Study of freeze-dried quercetin-CD binary systems by DSC FT-IR, X-RD and SEM analysis. J. Pharm. Biomed Anal 2004; 34: 333–339
- Rajewski R. A., Stella V. J. Pharmaceutical applications of Cyclodextrins 2. In vivo drug delivery. J. Pharm. Sci. 1996; 85(11)1142–1168
- Read M. A. Flavonoids: Naturally occurring anti-inflammatory agents. American Journal of Pathology 1995; 147(2)235–237
- Stella V. J., Rajewski R. A. Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 1997; 14: 556–567
- Guo Xilang, Yu Yang, Guoyan Zhai, Guomei Zhang, Jianbin Chao, Shaomin Shuang. Study on inclusion interaction of piroxicam with β-cyclodextrin derivatives. Spectrochim Acta A Mol. Biomol. Spectrosc. 2003; 59(14)3379–3386
- Zheng Ying, Haworth I. S., Zuo Zhong, Chow M. S. S., Chow A. H. L. Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes. J. Pharm. Sci. 2005; 94(5)1079–1086